Biosite and Oxford Genome Sciences Announce Collaboration in Colorectal Cancer
04 April 2006 - 8:00PM
PR Newswire (US)
SAN DIEGO and OXFORD, England, April 4 /PRNewswire-FirstCall/ --
Biosite(R) Incorporated (NASDAQ:BSTE) and privately-held Oxford
Genome Sciences (UK) Ltd. (OGeS) today announced a collaboration
for the evaluation of protein-based disease markers for colorectal
cancer. The markers could be used for the development of potential
blood-based diagnostic products aimed at expanding personalized
therapeutic options for colorectal cancer. In particular, these
blood-based diagnostics would be designed to enable the early
identification of colorectal cancer patients that have relapsed,
thus enabling clinicians to select the most appropriate therapeutic
option. Today, the fecal occult blood test and colonoscopy, a
highly invasive procedure, are the most frequently used screening
and diagnostic methods for colorectal cancer, which has a 30 to 40
percent recurrence rate within an average of 18 months after
primary diagnosis. (1,2,3,4) OGeS has developed a database (the
Oxford Genome Anatomy Project or OGAP(R)) that integrates genomic,
proteomic and clinical information derived from blood and tissue
studies for a large number of diseases. Under the terms of the
collaboration, OGeS will identify at least 25 proteins discovered
in blood and tissue samples from relapsing colorectal cancer
patients and Biosite will have the rights to develop blood-based
diagnostic tests using one or more of those biomarkers. Financial
terms of the agreement were not disclosed. "We are increasingly
interested in studying selected areas of cancer that can benefit
from rapid, effective, non-invasive diagnostic technologies," said
Kim Blickenstaff, Biosite's chairman and chief executive officer.
"This collaboration expands our research aimed at evaluation of
diagnostic tools for relapsing colorectal cancer by providing us
with access to high quality validation of potentially valuable
protein biomarkers." "Relapsing disease is the major cause of
suffering and death in colorectal cancer patients and there is a
complete lack of clinical tools to aid physicians in the process of
deciding whom to treat when and whether to treat with
chemotherapy," said Christian Rohlff, OGeS' chief executive
officer. "This collaboration with Biosite underpins our corporate
objective of applying new strategies to the emerging field of
personalized medicine in oncology to improve patient outcomes."
More than 1 million Americans have colorectal cancer and more than
140,000 new cases are diagnosed each year. More than 55,000 people
died from cancers of the colon/rectum in 2005. Estimated healthcare
costs related to treatment for colorectal cancer in the United
States are more than $8 billion.(5) Patients with a primary
diagnosis of colorectal cancer are followed up on average every
three to six months for the first three years and every six months
for the next two years to assess recurrence.(6) About Oxford Genome
Sciences Oxford Genome Sciences (OGeS) is focused on the
development of personalised medicines, mainly for oncology
indications. The Company has developed a unique integrated platform
that combines genomic, proteomic and clinical information to
accelerate the discovery and validation of drug targets and
biomarkers in human beings. The benefits are improved biomarkers
for patient selection, drug response and efficacy monitoring, and
the integration of diagnostics into drug development and product
launch, thereby facilitating more accurate drug development and
providing cost and time savings. OGeS' strategy is to enter into
flexible strategic alliances to capture maximum value from its
unique and integrated platform for the development of new
therapeutics and diagnostics in the field of cancer. In parallel,
the Company provides target and biomarker discovery and screening
services to pharmaceutical and biotechnology companies providing
OGeS with short-term revenues. OGeS was formed in 2004 and is based
near Oxford, UK. http://www.oxfordgenomesciences.com/ About OGAP(R)
OGAP holds the world's largest proprietary collection of proteins
represented by the database, which contains over 1 million peptide
sequences from 50 tissues and 60 disease states, mapped to
approximately 15,000 genes and over 8 million single nucleotide
polymorphism and haplotypes. The database can be customised for
individual partners to support and enhance their preclinical and
clinical drug development activities. About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company
commercializing proteomics discoveries for the advancement of
medical diagnosis. The Company's products contribute to
improvements in medical care by aiding physicians in the diagnosis
of critical diseases and health conditions. Biosite's Triage(R)
rapid diagnostics are used in approximately 50 percent of U.S.
hospitals and in more than 50 international markets. Information on
Biosite can be found at http://www.biosite.com/. Except for the
historical information presented herein, matters discussed in this
press release are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially
from any future results, performance or achievements expressed or
implied by such statements. Statements that are not historical
facts, including but not limited to statements that are preceded
by, followed by, or that include the words "will"; "believes";
"should"; "intends"; "anticipates"; "plans"; "expects";
"estimates"; or similar statements are forward-looking statements.
Forward looking statements include statements about the potential
benefits of the collaboration to Biosite and Oxford Genome Sciences
and Biosite's ability evaluate the diagnostic utility of the
biomarker targets. In addition, there can be no guarantees that
Biosite will develop any diagnostic product in the field of
colorectal cancer or any other form of cancer. Even if Biosite
believes it has initially developed such a product, Biosite may not
be able to complete the development or obtain the regulatory
approvals to commercialize the product. Risks that should be
considered include risks and uncertainties regarding the discovery
and product development process generally, risks associated with
the introduction of competitive products from companies with
greater capital and resources, uncertainties around the proprietary
nature of the targets subject to the collaboration, and risks and
expenses associated with litigation, contract disputes, patent
conflicts, changes in reimbursement policies, regulatory changes,
and the other risks detailed in Biosite's most recent Annual Report
on Form 10-K, and other SEC filings. Biosite disclaims, any intent
or obligation to update these forward-looking statements. Copies of
Biosite's public disclosure filings are available from its investor
relations department. Biosite(R), Omniclonal(R), Triage(R) and New
Dimensions in Diagnosis(R) are registered trademarks of Biosite
Incorporated. The Company's logo is a trademark of Biosite
Incorporated. OGAP(R) is a registered trade mark of Oxford Genome
Sciences (UK) Ltd (1) Desch, CE, Benson, III, AB, Somerfield, MR,
Flynn, PJ, Krause, C, Loprinzi, CL, Minsky, BD, Pfister, DG, Virgo,
KS, Petrelli , NJ. Colorectal Cancer Surveillance: 2005 Update of
an American Society of Clinical Oncology Practice Guideline.
Journal of Clinical Oncology, Vol 23, No 33 (November 20), 2005:
pp. 8512-8519. (2) Guyot et al. Time trends in the treatment and
survival of recurrences from colorectal cancer. Ann Oncol.2005; 16:
756-761 (3) Chuwa EW, Seow-Choen F. Outcomes for abdominoperineal
resections are not worse than those of anterior resections. Dis
Colon Rectum. 2006 Jan;49(1):41-9. (4) Incidence and Prevalence
Database, 2005. (5) Cancer Trends Progress Report - 2005 Update,
National Cancer Institute, NIH, DHHS, Bethesda, MD, December 2005,
http://progressreport.cancer.gov/. (6) Desch CE et al. Colorectal
Cancer Surveillance: 2005 Update of an American Society of Clinical
Oncology Practice Guideline. Journal of Clinical Oncology. November
20, 2005;23(33): 8512-8519. DATASOURCE: Biosite Incorporated;
Oxford Genome Sciences (UK) Ltd CONTACT: Nadine Padilla, VP,
Corporate & Investor Relations, +1-858-805-2820, , or Nicole
Beckstrand, Manager, Public Relations, +1-858-805-2803, , both of
Biosite Incorporated; or Christian Rohlff, Chief Executive Officer
of Oxford Genome Sciences (UK) Ltd, +44 (0) 1235 861770, ; or David
Dible, or Valerie Auffray, , both of Citigate Dewe Rogerson, +44
(0)207 638 9571, for Oxford Genome Sciences Web site:
http://progressreport.cancer.gov/ Web site:
http://www.oxfordgenomesciences.com/ Web site:
http://www.biosite.com/ Company News On-Call:
http://www.prnewswire.com/comp/116737.html
Copyright
Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Jul 2024 to Jul 2024
Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Jul 2023 to Jul 2024